Disclosure Of Entity's Operating Segments [Text Block]

Egetis Therapeutics - Filing #5995613

Concept As at
2024-12-31
2024-01-01 to
2024-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
Disclosure of entity's operating segments [text block]
NOT 6
Disclosure of operating segments [text block]
Disclosure of operating segments [abstract]
Disclosure of operating segments [line items]
Tax expense (income)
3,000,000 SEK
1,000,000 SEK
Profit (loss) before tax
3,432,000,000 SEK
3,268,000,000 SEK
Profit (loss)
3,436,000,000 SEK
3,269,000,000 SEK
Assets
7,923,000,000 SEK
7,602,000,000 SEK
Cash flows from (used in) operating activities
2,279,000,000 SEK
2,784,000,000 SEK
Cash flows from (used in) investing activities
12,000,000 SEK
0 SEK
Cash flows from (used in) financing activities
2,709,000,000 SEK
4,589,000,000 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.